Biplab Dasgupta
Distinguished Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Ongoing studies suggest that letrozole (LTZ), a drug used in the treatment of breast cancer, can potentially be repurposed as a novel therapeutic for glioblastoma (GBM). In a phase 0/I trial in patients with recurrent GBM, we observed that LTZ permeates into the GBM tissue and triggers dose-dependent changes in the expression of genes regulating the cell cycle [e.g., cyclin-dependent kinase (CDK) inhibitor 2A/2B , CDK4 ]. Based on these observations, we hypothesized that a combination of CDK4/6 inhibitors and LTZ may result in synergistic anti-GBM activity. Therefore, we assessed the antitumor effects of LTZ in combination with ribociclib, a third-generation CDK4/6 inhibitor, and the brain pharmacokinetics of ribociclib. Using cell viability and neurosphere growth assays against a panel of patient-derived GBM lines, both compounds were found to be cytotoxic when used as single agents and were strongly synergistic when used in combination. We then assessed the DNA-damaging effects (γH2AX induction), cell-cycle arrest, and the induction of apoptosis (Annexin V-FITC/propidium iodide) of both compounds as single agents and when used in combination. LTZ potentiated ribociclib-induced DNA damage and cell-cycle arrest, leading to apoptosis. Systemic and brain pharmacokinetic analysis of ribociclib in Sprague-Dawley rats by serial blood and brain extracellular fluid sampling showed that ribociclib penetrates the blood-brain barrier with a partitioning coefficient (K pu,u,brain ) of about 10%. Overall, our studies suggest that a combination of ribociclib and LTZ is likely to be strongly synergistic against GBM at concentrations of the drugs that can be achieved in the brain.
Year:
2026
PTEN-deficient patient-derived sphere growth is inhibited by combination S6K1 and AXL inhibition. A, JHH136 patient-derived GBM were treated for 72 hours with 10 μmol/L LY-2584702 and/ or 10 μmol/L BMS-777607. Phase contrast images show reduced sphere size with inhibitor combination compared with single inhibitor treatment and vehicle control ( n = 3). Scale bar, 100 μm. B, Quantification of spheres in three independent cultures as in A are shown. P values from t tests indicate combination efficacy compared with single agent controls. C, Mayo59 treated with 10 μmol/L LY-2584702 and/or 10 μmol/L BMS-777607 for 7 days. Combination treatment reduced sphere size and induced an altered morphology ( n = 3). Scale bar, 200 μm. D, Quantification of images in C shows significant reduction in sphere size in combination-treated spheres. E, Symptom-free survival of mice bearing intracranial tumors of Mayo59 PDX treated with vehicle or a combination of LY-2584702 and BMS-777607 together. Survival curve shows that animals gained a sustained delay in disease from combination treatment ( n = 10 per group). F, Cox proportional hazard ratio analysis for mice in E . Log-rank score for combination treatment is below 0.002.
Year:
2024
Targeting requirements in the S6K1/S6K2 network. A and B, S6 phosphorylation was reduced only upon genetic silencing of both S6K1 and S6K2 in LN229 GBM cells. C, Combined inactivation of S6K1 and S6K2 via sgRNA and siRNA was required to silence S6K signaling in PTEN-deficient GBM U87MG-GFP-Luc. D, DepMap correlation shows dependence on S6K1 and S6K2 when PTEN is mutated. E, PTEN inactivation caused an induction of S6K signaling seen as an increase in the phosphorylation of rpS6. This increase can only be abrogated by combination inactivation of both S6K1 (exon 5) and S6K2 (exon 9). F, sgNT and sgS6K1 GBM LN229 cells were treated with 10 μmol/L LY-2584702 or 10 μmol/L PF-4708671 for 3 hours. Inhibitor suppression of phospho-rpS6 was modestly improved by knockout of S6K1. G, sgNT and sgS6K2 GBM LN229 cells were treated as in F . Inhibitor suppression of phospho-rpS6 was significantly enhanced by S6K2 knockout. H, sgNT and sgS6K2 (exon 9) LN229 cells transfected with siNT or siPTEN for 72 hours were incubated with S6K1 inhibitors for 3 hours. PTEN inactivation induced phospho-rpS6, which was blocked by the combination of sgS6K2 and an S6K1 inhibitor.
Year:
2024
S6K2 and AXL have an effector—regulator relationship. A, GSEA identified an AXL response signature in RNA sequence analysis of sgS6K2 LN229 GBM cells. B and C, sgNT or sgS6K2 (exon 9) GBM U87MG-GFP-Luc ( B ) or LN229 ( C ) cells were stimulated with 300 nmol/L Phosphatidylserine (PtdSer) and/or 400 ng/mL Gas6 for 45 minutes as indicated. AXL autophosphorylation of pY702 was increased in the absence of S6K2. D, KiNativ analysis represented as a dendrogram (CORAL kinome tree) in which kinase inhibition in combination-treated shPTEN LN229 cells compared with vehicle is expressed as increased node size, branch intensity, and node intensity. Combination treatment with 10 μmol/L LY-2584702 and 10 μmol/L BMS-777607 for 3 hours specifically targeted S6K1, AXL, and MET. E, Model showing S6K2 as both a signaling effector and a feedback regulator of AXL. F, siPTEN LN229 sgNT or sgS6K2 cells were treated for 3 hours with 10 μmol/L LY-2584702 and/or 10 μmol/L BMS-777607 as indicated. S6K2 genetic deletion increased AXL phosphorylation. Combination of LY-2584702 with BMS-777607 was required to reduce both rpS6 and AXL phosphorylation. G, Mayo59 gliomaspheres were transfected with siNT or independent siS6K2 duplexes prior to treatment with 10 μmol/L LY-2584702 and/or 10 μmol/L BMS-777607 for 3 hours as indicated. Treatment with LY-2584702 reduced rpS6 phosphorylation and S6K2 genetic inactivation resulted in increased AXL, consistent with the requirement for combination with BMS-777607 in reducing GBM growth.
Year:
2024
S6K1 and AXL inhibitors counteract pyrimidine biosynthesis in PTEN-deficient GBM. A, Steady state metabolite abundance in LN229 GBM transfected with siPTEN and then treated with vehicle control or combination S6K1 (LY-2584702, 10 μmol/L) and AXL (BMS-777607, 10 μmol/L) inhibitors for 5 hours ( n = 4). B, Detail of nucleotide and their precursor metabolites from A . C, log 2 fold change of [U]- 13 C glucose labeled metabolites in U87MG GBM pretreated for 3 hours with 10 μmol/L LY-2584702 and 10 μmol/L BMS-777607 vs. vehicle control at 60 and 300 minutes after addition of 13 C-glucose ( n = 4). Statistically significant (>1.5 fold) metabolites are highlighted. D, JHH136 spheres were treated with inhibitors (10 μmol/L each) for 72 hours for western blot analysis. LY-2584702, S6K1 inhibitor, reduces phosphorylation of rpS6 and CAD leading to sustained impairment of pyrimidine synthesis and cell growth. Treatment with BMS-777607 increases H2A.X phosphorylation at Serine 139, indicating an increase in double-stranded DNA breaks. E, Mayo59 spheres were treated as in D . S6K1 inhibition reduces phosphorylation of rpS6 and CAD, impairing pyrimidine synthesis. DNA damage is evident in combination S6K1 and AXL inhibition.
Year:
2024
Targeting requirements in the S6K1/S6K2 network. A and B, S6 phosphorylation was reduced only upon genetic silencing of both S6K1 and S6K2 in LN229 GBM cells. C, Combined inactivation of S6K1 and S6K2 via sgRNA and siRNA was required to silence S6K signaling in PTEN-deficient GBM U87MG-GFP-Luc. D, DepMap correlation shows dependence on S6K1 and S6K2 when PTEN is mutated. E, PTEN inactivation caused an induction of S6K signaling seen as an increase in the phosphorylation of rpS6. This increase can only be abrogated by combination inactivation of both S6K1 (exon 5) and S6K2 (exon 9). F, sgNT and sgS6K1 GBM LN229 cells were treated with 10 μmol/L LY-2584702 or 10 μmol/L PF-4708671 for 3 hours. Inhibitor suppression of phospho-rpS6 was modestly improved by knockout of S6K1. G, sgNT and sgS6K2 GBM LN229 cells were treated as in F . Inhibitor suppression of phospho-rpS6 was significantly enhanced by S6K2 knockout. H, sgNT and sgS6K2 (exon 9) LN229 cells transfected with siNT or siPTEN for 72 hours were incubated with S6K1 inhibitors for 3 hours. PTEN inactivation induced phospho-rpS6, which was blocked by the combination of sgS6K2 and an S6K1 inhibitor.
Year:
2024
S6K2 and AXL have an effector—regulator relationship. A, GSEA identified an AXL response signature in RNA sequence analysis of sgS6K2 LN229 GBM cells. B and C, sgNT or sgS6K2 (exon 9) GBM U87MG-GFP-Luc ( B ) or LN229 ( C ) cells were stimulated with 300 nmol/L Phosphatidylserine (PtdSer) and/or 400 ng/mL Gas6 for 45 minutes as indicated. AXL autophosphorylation of pY702 was increased in the absence of S6K2. D, KiNativ analysis represented as a dendrogram (CORAL kinome tree) in which kinase inhibition in combination-treated shPTEN LN229 cells compared with vehicle is expressed as increased node size, branch intensity, and node intensity. Combination treatment with 10 μmol/L LY-2584702 and 10 μmol/L BMS-777607 for 3 hours specifically targeted S6K1, AXL, and MET. E, Model showing S6K2 as both a signaling effector and a feedback regulator of AXL. F, siPTEN LN229 sgNT or sgS6K2 cells were treated for 3 hours with 10 μmol/L LY-2584702 and/or 10 μmol/L BMS-777607 as indicated. S6K2 genetic deletion increased AXL phosphorylation. Combination of LY-2584702 with BMS-777607 was required to reduce both rpS6 and AXL phosphorylation. G, Mayo59 gliomaspheres were transfected with siNT or independent siS6K2 duplexes prior to treatment with 10 μmol/L LY-2584702 and/or 10 μmol/L BMS-777607 for 3 hours as indicated. Treatment with LY-2584702 reduced rpS6 phosphorylation and S6K2 genetic inactivation resulted in increased AXL, consistent with the requirement for combination with BMS-777607 in reducing GBM growth.
Year:
2024
S6K1 and AXL inhibitors counteract pyrimidine biosynthesis in PTEN-deficient GBM. A, Steady state metabolite abundance in LN229 GBM transfected with siPTEN and then treated with vehicle control or combination S6K1 (LY-2584702, 10 μmol/L) and AXL (BMS-777607, 10 μmol/L) inhibitors for 5 hours ( n = 4). B, Detail of nucleotide and their precursor metabolites from A . C, log 2 fold change of [U]- 13 C glucose labeled metabolites in U87MG GBM pretreated for 3 hours with 10 μmol/L LY-2584702 and 10 μmol/L BMS-777607 vs. vehicle control at 60 and 300 minutes after addition of 13 C-glucose ( n = 4). Statistically significant (>1.5 fold) metabolites are highlighted. D, JHH136 spheres were treated with inhibitors (10 μmol/L each) for 72 hours for western blot analysis. LY-2584702, S6K1 inhibitor, reduces phosphorylation of rpS6 and CAD leading to sustained impairment of pyrimidine synthesis and cell growth. Treatment with BMS-777607 increases H2A.X phosphorylation at Serine 139, indicating an increase in double-stranded DNA breaks. E, Mayo59 spheres were treated as in D . S6K1 inhibition reduces phosphorylation of rpS6 and CAD, impairing pyrimidine synthesis. DNA damage is evident in combination S6K1 and AXL inhibition.
Year:
2024
Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.
Year:
2024
Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (14)
Cristina Andreani
Assistant professor
University of Cincinnati
Mario Medvedovic
Professor
University of Cincinnati
Nicholas Clark
Senior Staff Scientist
Fred Hutch Cancer Center
Xiaoyang Qi
Professor
University of Cincinnati
Soma Sengupta
Chair
Tufts Medical Center
Zalfa A. Abdel‐Malek
-
Pankaj Desai
Professor of Pharmacokinetics and Director, Drug Development Graduate Program
University of Cincinnati
Nicole Oatman
Ghent University
Timothy N. Phoenix
Assistant Professor
University of Cincinnati
Angelo D'Alessandro
Full Professor
University of Colorado Anschutz Medical Campus
Trisha M. Wise-Draper
University of Cincinnati
Pranjal Sarma
RESEARCH SCIENTIST
University of Cincinnati
Pier Paolo Scaglioni
Professor
University of Cincinnati College of Medicine
Ravi Amaravadi
Associate Professor, Clinician-Educator
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.